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Available online 4 June 2016Huntington's disease (HD) is a genetically-mediated neurodegenerative disorder wherein the aetiological defect
is a mutation in the Huntington's gene (HTT), which alters the structure of the huntingtin protein (Htt) through
lengthening of its polyglutamine tract, thus initiating a cascade that ultimately leads to premature death. How-
ever, neurodegeneration typicallymanifests inHDonly inmiddle age, andmechanisms linking the causativemu-
tation to brain disease are poorly understood. Brain metabolism is severely perturbed in HD, and some studies
have indicated a potential role for mutant Htt as a driver of these metabolic aberrations. Here, our objective
was to determine the effects of HD on brain metabolism by measuring levels of polar metabolites in regions
known to undergo varying degrees of damage. We performed gas-chromatography/mass spectrometry-based
metabolomic analyses in a case-control study of eleven brain regions in short post-mortem-delay human tissue
from nine well-characterized HD patients and nine matched controls. In each patient, we measured metabolite
content in representative tissue-samples from eleven brain regions that display varying degrees of damage in
HD, thus identifying the presence and abundance of 63 different metabolites from several molecular classes, in-
cluding carbohydrates, amino acids, nucleosides, and neurotransmitters. Robust alterations in regional brain-
metabolite abundances were observed in HD patients: these included changes in levels of small molecules that
play important roles as intermediates in the tricarboxylic-acid and urea cycles, and amino-acid metabolism.
Our ﬁndings point to widespread disruption of brain metabolism and indicate a complex phenotype beyond
the gradient of neuropathologic damage observed in HD brain.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Neurodegenerative disease
Huntington's disease
Polyol pathway
Brain urea metabolism
Metabolic brain disease
Inositol pathway1. Introduction
Huntington's disease is an autosomal-dominant genetic disorder
caused by an expanded CAG repeat in exon 1 of the HTT gene, which
is located on chromosome 4 and encodes the huntingtin protein [1].
Clinically, HDmanifests with a triad of symptoms, including progressivevelopment and Experimental
tals NHS Foundation Trust,
r, UK, M13 9WL.
k (S. Patassini),
. This is an open access article undermotor dysfunction, cognitive decline, and psychiatric disturbance with
the age of onset inversely related to the repeat length [2,3]. The patho-
genic mechanism causes marked degeneration of the caudate/putamen
region and eventually more widespread loss of cortical, prefrontal,
temporal, thalamic, cerebellar and hippocampal neurons with diffuse
shrinkage of brain tissue [4].
Biochemical pathways in which alterations have been linked to
expression of the mutant huntingtin protein (mHtt) are numerous,
and include impaired maintenance of energy metabolism [5]. Indeed,
HD-gene carriers can undergomarkedweight loss despite sustained ca-
loric intake, consistent with alterations in energy metabolism that con-
tribute to the pathological process [6]. Interestingly, the mechanisms
responsible for some of the metabolic abnormalities observed in HD
have been considered as potential targets for developing biomarkersthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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though some studies have suggested beneﬁcial potential of such drugs
in improving aspects of the metabolic disturbances in HD, clinical trials
have shown conﬂicting results [10,11]. The development of therapies
aimed at improving the energy deﬁcits in HD is challenging, since the
heterogeneous distribution of metabolic defects in HD implies a com-
plex interaction involving both CNS and extra-cerebral organ systems
[12]. This complexity is exacerbated by the potential variation in meta-
bolic perturbations between different brain regions in HD-gene carriers
[13]. Although it is still uncertain exactly how CNS metabolism is inﬂu-
enced by the ubiquitously-expressed mHtt protein, it seems likely that
different brain regions have a heterogeneous response to the conse-
quent metabolic disturbance.
It is necessary to understand the metabolic pathways altered in HD
in order to better understand the link betweenmetabolic abnormalities
and pathogenesis. To date, however, detailed knowledge of the
metabolites contributing to these traits has been somewhat sparse.
Nor is it knownhow thesemetabolic alterations contribute to pathology
in distinct brain regions. Since few investigations into these aspects of
HD pathogenesis have been reported to date, it is therefore valuable to
address the following key questions: 1) to clarify whether metabolic
perturbations are present in a substantial number of different brain
regions in HD; 2) to determine whether putative defects represent
common or unique metabolic signatures among the different
regions of affected HD brain; and 3) to correlate those metabolite
changes with the degree of regional tissue damage known to occur in
HD brain.
In order to study the metabolic effects occurring in HD across
different regions of affected brain, we chose to apply gas chromatogra-
phy/mass spectrometry (GC–MS) to detect and characterise putative
alterations in polar metabolite levels in a case-control approach in
short post-mortem-delay brain tissue of patients and matched controls.
To our knowledge, this is the ﬁrst time that an untargeted GC–MS-
based global metabolomic approach has been used to proﬁle polar
metabolite alterations in a large number of HD human brain regions.
While metabolite analysis has been used to proﬁle bioﬂuids from indi-
viduals affected with HD (sometimes with conﬂicting results [14,15]),
available human brain post-mortem studies are relatively few, because
high-quality tissue is difﬁcult to procure.
For this study, human-brain tissuewas obtained from the Neurolog-
ical Foundation of NewZealandHumanBrain Bank,which has extensive
experience in the characterization and storage of high quality brain
samples [16,17]. Here, eleven regions of the human brain underwent
metabolomic analyses in a case-control study. To accurately describe
themetabolic impact of HDpathology, the regions selectedwere chosen
to provide a comprehensive representation of the heterogeneous range
of degeneration that occurs in HD brain. The putamen andmotor cortex
were included, as they are severely affected during the disease progres-
sion; sensory cortex, globus pallidus, cingulate gyrus, and substantia
nigra were also included, since they are known to be moderately
affected; lastly, hippocampus, entorhinal cortex, cerebellum, middle
frontal gyrus, and middle temporal gyrus were also studied, as they
have not been commonly linked to major neurodegeneration in this
context [18,19].2. Materials and methods
2.1. Acquisition of human brains
Whole brains from nine HD patients and nine matched controls
were obtained from the Neurological Foundation of New Zealand
Human Brain Bank at the University of Auckland. All procedures
employed in this study were approved by the University of Auckland
Human Participants Ethics Committee with informed consent from all
families.2.2. Human brain tissue
Each brainwas dissected under the supervision of expert neuroanat-
omists who accurately identiﬁed and pre-dissected each of the brain
regions studied (Suppl. Fig. 1). We obtained tissue from eleven
identiﬁed regions: putamen, PUT; motor cortex, MCTX; sensory cortex,
SCTX; globus pallidus, GP; cingulate gyrus, CG; substantia nigra, SN;
middle frontal gyrus, MFG; middle temporal gyrus, MTG; cerebellum,
CB; hippocampus, HP; and entorhinal cortex, ENT. Tissue samples of
50 ± 5 mg, were dissected from each region from each patient, and
stored at−80 °C until analysis.
2.3. Tissue extraction
Aliquots of 50 ± 5 mg brain tissue underwent a Folch-style
extraction using a TissueLyser bead homogeniser (Qiagen; UK). Each
sample was extracted in 0.8 ml 50:50 (v/v) methanol:chloroform, to
which a solution of the labelled internal standards (Citric acid-d4,
13C6-D-fructose, L-tryptophan-d5, L-alanine-d7, stearic acid-d35, benzoic
acid-d5, and leucine-d10) in methanol had been added to achieve a
ﬁnal concentration of 0.016 mg/ml of each internal standard in the
extraction solvent, for 10 min at 25 Hz with a single 3-mm tungsten
carbide bead. Samples corresponding to each brain regionwere handled
as single separate batches for this and all subsequent procedures. Phase
separationwas achieved by addition of 0.4mlwater followed by vortex-
mixing (10–15 s) and centrifugation (2400 g, 5 min), and subsequent
removal of the chloroform layer. Extraction blanks were prepared by
including tubes without tissue samples in each batch.
2.4. Sample preparation
From the methanol:water supernatant, 200-μl aliquots were trans-
ferred to pre-labelled tubes. For each brain region, quality control repli-
cates (QC) were prepared pooling equal amounts of extract (200 μl)
from each sample. After brief mixing, 200-μl aliquots of each sample
were dried (30 °C, 16–18 h) in a Speedvac centrifugal concentrator
(Thermo Scientiﬁc). Dried residues were then held in sealed tubes at
4 °C until derivatization for GC–MS analysis.
2.5. GC–MS analysis
The method used was based upon one that we previously described
[20,21]. Brieﬂy, this method uses methoximation and trimethylsilylation
to generate a proﬁle of polar small-molecule metabolites such as those
corresponding to amino acids, simple organic acids and monosaccha-
rides, and is typically applied to provide comparative data in a case-
control experimental design [22].
Dried residues were reconstituted in 60-μl methoxylamine
hydrochloride solution (20 mg/ml in dry pyridine) and heated at
80 °C for 20 min in sealed tubes. 60 μl of N-methyl-N-(trimethylsilyl)
triﬂuoroacetamide (MSTFA) was then added and heating continued at
80 °C for a further 20min. Finally, 10 μl of a retention-timemarker solu-
tion (nine n-alkanes covering the range C12-C32 dissolved at 10 mg/ml
in 1:1 hexane:pyridine) was added and the solutions transferred to
autosampler vials for GC–MS analysis.
Chromatography was carried out using an Agilent/J&W DB17-MS
column (30 m × 0.25 mm × 0.25 μm) with a 3 m × 0.25 mm retention
gap, and helium carrier at a constant ﬂow of 1.4 ml/min. Oven temper-
aturewas progressively increased from50 °C to 300 °C at 10 °C /min. 1 μl
injections were performed in Pulsed-Splitless mode using an MPS2
autosampler (Gerstel; Germany), and a 7890A Gas Chromatograph
with Split/Splitless inlet (Agilent; USA). Column efﬂuent was analysed
using a Pegasus HT time-of-ﬂight mass spectrometer (LECO; UK),
acquiring 10 spectra/s over the mass range of 45–800 Da.
This study was performed in a series of single-batch experiments,
wherein each speciﬁc brain region constituted a batch. Within each
Table 1
Study-group characteristics.
Variable Control HD
Number 9 9
Male:female ratio 6:3 6:3
Age (y; ±95% CI) 67.4 (60.0–74.9) 65.2 (57.3–73.2)
PMD (h; ±95% CI) 10.6 (8.1–13.1) 11.2 (9–13.4)
Brain-weight (g; ±95% CI) 1322 (1249–1396) 1104 (938–1270)*
Data are means (±95% CI). Abbreviation: PMD, post-mortem delay.
⁎ P= 0.01
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sequence interleaved with injections of the pooled QC samples and
extraction blanks. Extraction blanks were inspected visually to conﬁrm
absence of carryover.
2.6. Data analysis
Data were prepared using the ‘Reference Compare’ method within
ChromaTOF 4.5 (LECO). Databases we employed were: the NIST Mass
Spectral Reference Library (NIST08/2008; National Institute of
Standards and Technology/Environmental Protection Agency/National
Institutes of Health Spectral 262 Library; NIST, Gaithersburg, MD,
USA); and theGolmMetabolomeDatabase (Max Planck Institute ofMo-
lecular Plant Physiology, Potsdam-Golm, Germany). Chromatographic
retention-timedatawere available fromour library reference standards.
Matching of bothmass spectra/expected retention time and peak-shape
integration was manually veriﬁed by two independent investigators to
constitute a deﬁnitive molecular identiﬁcation. Pooled QC samples
were chosen as representative of the human brain to generate a ﬁnal
list of metabolites. For all the brain regions analysed here the same
reference list was used. In total 142 metabolite features were originally
selected from the GC–MS chromatogram. After removal of duplicates
(e.g. two isomeric peaks for glucose) and unidentiﬁed IDs, the remain-
ing 63 identiﬁed metabolites were analysed and reported in this
study. A representative GC–MS chromatogram is shown in Suppl. Fig. 2.
2.7. Statistical methods
Data analysis was performed by transforming the GC–MS raw data
in log10 space. For each brain region a multivariate principal-
components analysis (PCA) was performed on the entire metabolite
list to assess the quality of the dataset generated (SIMCA-P; UMetrics
AB). Statistical signiﬁcance was calculated using multiple 2-tailed
t-tests and corrected for potential effects ofmultiple comparisons by ap-
plying a false-discovery rate (FDR) 10% correction [23]. Fold-changes in
metabolite abundances were calculated as the ratio of themean of each
group, and have been presented as HD group/control group ratios.
For each brain region, the potential effect of the mutant allele HTT
CAG repeat size on brain metabolites was also investigated by generat-
ing pair-wise correlations between the number of CAG triplets versus
the relative abundance of each metabolite (log10-transformed) in con-
trols and HD groups using the statistical discovery software JMP® (Ver-
sion 12.0.0; SAS). Since the number of cases analysed in this study is
relatively limited, a conservative analysis was used in order to generate
credible results. First of all, the values for each metabolite-CAG couple
were visually depicted in a scatterplot matrix. Then, the strength of
each correlation was veriﬁed by applying a simple bootstrap analysis.
If the correlation coefﬁcient (r) generated was in the range of r values
N0.6 (or b−0.6) after bootstrap analysis, the determined metabolite-
CAG pair correlation was considered reliable. Finally, a correlation was
considered signiﬁcant only if both r values and P-values were at least
N0.8 (or b−0.8) and b0.01, respectively. Similar criteria were used to
investigate the inﬂuence of age and post-mortem delay (PMD) on
metabolite abundances in human brain.
3. Results
Here we measured the relative abundance of 63 well-deﬁned me-
tabolites in post-mortem samples from 11 brain regions from 9 patients
with HD and 9 matched controls. Cases and controls were matched for
male:female ratio, age, and PMD (Table 1). As expected, brain-weights
were signiﬁcantly lighter in cases than in controls (P=0.01), consistentFig. 1. Principal component analysis (PCA) of the eleven human brain regions examined by GC–
HD cases (red diamond). The relatively dense clustering observed between the QC measurem
method applied for metabolite proﬁling in this study. The dimensions used for principal compwith late-stage disease. Lastly, HD cases were all heterozygotes for HTT
mutations, with expanded polyglutamine tract-lengths ranging
between 40 and 47 (Suppl. Table 1).
The reproducibility of our GC–MS analysis was veriﬁed by monitor-
ing the metabolite measurements of sample replicates (N = 5–7). In
each brain region, limited technical variability was observed, even for
low abundancemetabolites, supporting thequality of thedataset gener-
ated (Suppl. Table 2; Suppl. Fig. 3).
To investigate whether the overall metabolite proﬁle was different
between HD and control brain, multivariate PCA analysis was per-
formed for each brain region. As shown in Fig. 1, PCA analysis demon-
strated a good class separation between HD gene-carriers and controls
and the clustering of QC replicates suggests that technical variability is
satisfactory in each brain region. Interestingly, a single HD case did not
cluster together with either controls or HD cases. As clinical records
did not indicate any valid reason for exclusion, we considered this pa-
tient as representative of the natural variability occurring in the HD
human condition and therefore, the case was included in our subse-
quent analyses.
Following the assessment of sample quality and GC–MS reproduc-
ibility, the alterations in metabolite levels were investigated in HD
brain. In total, 63metabolites weremonitored and 48 of these were sig-
niﬁcantly altered in abundance in at least one brain region. Among the
metabolites identiﬁed as differentially abundant are key components
of relevant biological pathways such as sugar metabolism, brain energy
transduction, urea cycle, and amino-acid and nucleoside metabolism
(Table 2; Suppl. Tables 3, 4).While the putamen (the regionmost affect-
ed by HD) showed the highest number of metabolites signiﬁcantly al-
tered in disease, the number of changes observed in other regions
indicates a lack of correlation with the severity of pathology in HD
brain (Fig. 2). Notably, polyol-pathway intermediates and amino acids
were among those metabolite groups particularly affected in HD brain.
In fact, marked accumulation of glucose, sorbitol and fructose was pres-
ent in HD-mutation carriers, especially in those regions afﬁliated with
the basal-ganglia loop; moreover, with the exception of the aromatic
amino acids (tryptophan, tyrosine, and phenylalanine) and the
relatively-obscure pyroglutamic acid, most other amino acids detected
by our methodology tended to uniformly decrease in all brain regions
examined. Similarly, the neurotransmitters gamma-aminobutyric acid
(GABA) and its closely related precursor, 4-hydroxybutyric acid
(GHB), are largely decreased in HD brain. These ﬁndings taken together,
point to the existence of marked alterations in metabolism of amino
acids and neurotransmitters in HD brain which require closer inspec-
tion. Thus, as metabolite interactions represent important components
of biological processes, the study of how metabolic pathways generate
or utilise these metabolites may help to elucidate the underlying
molecular mechanisms in metabolic networks that contribute to the
pathogenesis of HD [24,25].
To further investigate these perturbations in our study, an explorato-
ry pair-wise Pearson-correlation analysis was performed using all the
well-identiﬁed metabolites, and the results of controls and HD casesMS. PCA plots showing class separation in 11 brain regions of controls (blue diamond) and
ents (black cross) supports the low variability and the good reproducibility of the GC–MS
onent analysis were PC1 and PC2.
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Table 2
Group of metabolites altered in abundance across the eleven human brain regions in HD cases. The list of metabolites altered in abundance in the HD brain is showed here by separate
classes. The values depicted in the table indicate the fold-change ratios of each metabolite in individual brain regions (HD group/control group). In bold are listed those metabolites sta-
tistically signiﬁcant after being tested bymultiple comparison analysis (FDR correction). Abbreviations: D, deﬁnitive (goodmass spectral match and retention index conﬁrmed by running
authentic standard on our instrument under the same GC conditions as used for the study); C, conﬁdent (goodmass spectral match to reference spectrum in NIST library for a compound
with a “unique” mass spectrum); P, putative (good mass spectral match to NIST library for a compound with a “generic” mass spectrum).
Group of metabolites PUT MCTX SCTX GP CG SN MFG MTG CB HP ENT
Glucose metabolites & pentoses
Fructose (D) 5.2 2.4 2.8 2.4 2 1.9 2.2 2.6 3.8 2 2.6
Sorbitol (D) 3.6 2.9 4.4 3 1.9 2.8 3.3 2.6 2.8 1.7 2
Glucose (D) 8.4 2.3 3.3 5.5 1.9 2.8 2.3 1.6 2.2 1.7 1.8
Glucose-6-phosphate (D) 13.1 1.6 1.4 6 3.7 5.1 3 2.7 2.7 3.4 7.7
Alternative fuel source
β-Hydroxybutyric acid (D) 2.4 1.9 3.1 1.8 2.1 2.2 2.3 2.6 1.9 1.9 2.1
Glycerol (D) 1 1 1 1.1 0.8 0.7 0.9 0.7 0.7 0.9 0.9
Threitol (D) 1.7 1.3 1.4 1.4 1.1 1.2 1.4 1.1 2.1 1.3 1.3
Glycerol-3-phosphate (D) 2.3 1.8 1.6 1.7 2.1 2.6 3.1 3 1.5 2.2 2.1
Glycerol-2-phosphate (P) 1.7 1.6 1.5 7 1.9 1.6 2.2 1.9 1.2 1.4 1.6
Scyllo-inositol (D) 1.2 0.8 0.7 1 0.8 0.8 0.9 0.7 0.6 0.7 0.6
Myo-inositol (D) 1.1 0.7 0.8 1.1 0.8 0.8 1 0.7 0.8 0.9 0.8
N-acetylglucosamine (C) 2.1 1.3 1.1 1.7 0.8 1.2 1.1 1 0.9 0.8 1.1
Ribitol (D) 0.5 0.6 0.6 0.7 0.6 0.6 0.8 0.7 0.6 0.7 0.7
TCA & Urea cycle and related
Fumaric acid (C) 2 2 1.5 1.5 1.4 1.4 1.8 1.5 1.7 1.3 1.5
Citric acid (D) 1.1 1 1.2 1 1.2 1.5 1.3 1.2 1.2 1 0.9
Malic acid (C) 2.1 1.1 1.4 1.2 1 1.2 0.9 1.1 1.4 0.6 0.8
Urea (D) 4.8 4.1 4.2 4.6 4.2 4.5 3.9 4.2 4.4 4.4 3.9
Ornithine (D) 0.5 0.6 0.6 0.6 0.6 0.6 0.5 0.9 1 0.4 0.5
N-acetylglutamic acid (D) 1 0.8 0.6 1 0.7 0.8 0.8 0.9 0.8 0.7 0.8
Creatinine (D) 0.8 0.9 0.9 0.9 0.9 0.9 1 0.7 0.8 0.8 0.8
Amino acids
Glycine (D) 1.6 0.9 0.7 0.6 1 1.1 0.8 0.6 0.3 0.6 0.8
Leucine (D) 0.8 0.8 0.9 0.8 0.8 0.7 0.7 0.9 0.5 0.5 0.7
Isoleucine (D) 0.8 0.8 0.7 0.7 0.7 0.7 0.6 0.6 0.5 0.5 0.7
Serine (D) 0.6 0.6 0.6 0.6 0.6 0.5 0.8 0.5 0.4 0.5 0.5
Threonine (D) 0.8 0.6 0.7 0.8 0.7 0.6 1 0.6 0.6 0.5 0.6
Aspartic acid (D) 0.6 1.3 0.9 0.7 0.7 0.7 0.9 0.9 0.8 0.8 0.8
Methionine (D) 1.2 1 0.9 1 0.9 0.9 0.9 0.9 0.6 0.6 0.7
Pyroglutamic acid (D) 1.6 1.1 1.1 1.4 1.1 1.4 1.3 1.3 1.1 1 1
Phenylalanine (D) 1.6 1.5 1.2 1.2 1 1.1 1.2 1.5 0.9 0.8 1.1
Proline (D) 0.4 0.5 0.4 0.5 0.4 0.6 0.4 0.5 0.3 0.3 0.4
N-acetylaspartic acid (D) 0.7 0.8 0.8 1 0.8 0.8 0.9 0.9 0.9 0.9 0.8
Lysine (D) 0.6 0.7 0.7 0.6 0.6 0.6 0.5 0.7 0.4 0.4 0.5
Tyrosine (D) 1.8 1.3 1.2 1.2 1.2 1.1 1 1.4 0.6 0.8 1.1
Tryptophan (D) 1.7 1.3 1.2 1.4 1.2 1.1 1.5 1.5 1.3 1 1.1
Glutamate (D) 1 1.1 1 1.3 0.9 0.9 1.1 0.9 1 1.1 0.8
Nucleosides
Uracil (C) 0.6 0.8 0.8 0.7 0.8 0.8 0.8 0.7 0.6 0.7 0.8
Hypoxanthine (D) 0.7 0.7 0.7 0.8 0.7 0.7 0.6 0.6 0.6 0.7 0.8
Guanosine (D) 1.4 3.5 2.4 0.8 1.5 0.7 4.5 0.9 1 0.9 1.7
Xanthine (C) 2.8 7.4 2.6 1.5 1.8 1.3 1.8 1.1 1 1 1.7
Inosine (C) 2.6 1.6 1.2 1.8 1.1 0.9 1.5 0.8 1.2 1 1.2
Miscellaneous
Ethanolamine (D) 0.6 0.8 0.8 0.7 0.5 0.6 0.6 0.5 0.5 0.5 0.6
Phosphoric acid (D) 0.8 0.6 0.7 1 0.7 0.6 0.8 0.6 0.7 0.8 0.7
GABA (D) 0.5 0.7 0.7 0.7 0.6 0.7 0.9 0.8 0.7 0.8 0.9
4-Hydroxybutyric acid (C) 0.6 0.7 0.5 0.2 0.3 0.4 0.7 0.5 0.3 0.6 0.6
Vitamin B5 (D) 0.5 0.6 0.5 0.4 0.5 0.4 0.6 0.6 0.6 0.5 0.6
Glutaric Acid (D) 2 0.6 0.8 3 0.8 0.9 0.8 0.8 0.9 0.8 0.8
Ethylene glycol (C) 0.6 0.7 1 0.6 0.3 0.6 0.2 0.7 0.5 0.6 0.5
Sugar phosphate (C) 2.1 1.4 1 1.6 1.1 1.2 2 1.1 0.9 1 1.1
1654 S. Patassini et al. / Biochimica et Biophysica Acta 1862 (2016) 1650–1662compared for each brain region (Fig. 3). While some differences were
present between the eleven brain-regions analysed for each group, a re-
peated pattern of correlated metabolites was noted in controls and HD
cases, respectively. In controls, many of the metabolite-pairs found to
be strongly correlated were participants or products of pathways relat-
ed to amino-acidmetabolism. These included leucine, isoleucine, serine,
threonine, aspartic acid, methionine, phenylalanine, proline, lysine, ty-
rosine and tryptophan, as well as 4-hydroxybutyric acid. Notably,
while most of the amino acids seem to be co-regulated in the control
cases, a small group of amino acids, namely glutamine, alanine, beta-alanine, cysteine and valine, were found to be not correlated with any
other amino acid in the same brain regions. New or additional strong
correlations were observed between pairs of metabolites that
participate in carbohydrate metabolism, amino-acid metabolism, and
other processes linked to energy supply in the HD cases (Fig. 3).
To determine how mHtt polyglutamine tract-lengths might
inﬂuence regional levels of brain metabolites, we investigated whether
any correlation existed between the number of HTT CAG repeats and
metabolite abundance in controls and HD cases. As the numbers in
each group were relatively low, only those metabolites showing a
Fig. 2. Number of alteredmetabolites in HD brain in each brain region. Graph showing the number of metabolites decreased (grey) and increased (white) for each brain region. The areas
analysedwere ranked in the graph from themost to the least severely affected by degeneration inHD (i.e. fromputamen to entorhinal cortex). The values showed on the right of the graph
bars represent the number of altered metabolites in each brain region expressed as the percentage of the total 63 metabolites identiﬁed and quantiﬁed by GC–MS in this study.
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corresponding P-values of b0.01) were considered signiﬁcant. Based
on this criterion, 5 metabolites were pin-pointed whose concentrations
strongly correlated with HTT CAG-repeat number: these were malic
acid and N-acetylglutamic acid in the control group, and myo-inositol,
glycine, and N-acetylaspartic acid in the HD group (Suppl. Table 5). No-
tably, these signiﬁcant correlations were limited to those brain regions
known to undergo severe degeneration in HD (Suppl. Table 5).
As striatal volume loss is known to correlate with HTT CAG-repeat
number in both premanifest and manifest HD [26,27], the ﬁnding of
myo-inositol (r=0.82; p=0.007) as the onlymetabolite strongly asso-
ciated with the pathological HTT CAG length in putamen merits further
investigation (Suppl. Fig. 4). A similar analysis was also performed to
determine whether any signiﬁcant correlation existed between the
abundance ofmeasuredmetabolites and the age/PMD of the cases stud-
ied. Taken together, our data indicate that neither age nor PMD inﬂu-
enced the metabolite abundances reported here (data not shown).
4. Discussion
Herewe report ourmetabolomic analysis of human tissue fromelev-
en different brain regions fromHDcases andmatched controls, to deter-
mine how metabolite levels might be differentially regulated in
different regions of disease-affected brain. This is the ﬁrst time, to our
knowledge, that an untargeted GC–MS-based global proﬁling analysis
of a large number of human-brain regions has been reported in HD. Fur-
thermore, we have also undertaken detailed mapping of themetabolite
alterations in speciﬁc brain regions in HD.
PCA analysis of the eleven brain regions showed minimal overlap
between the control and HD cases, suggestive of a widespread, severe
global effect of the HD mutation and/or downstream disease processes
on brain metabolism. Moreover, several imaging studies have support-
ed the view that there is a widespread effect on brain metabolism in
HD mutation-carriers [28,29]. However, the greater metabolite group
separation observed here in the putamen indicates that a more severe
metabolic perturbation has taken place in this brain region in HD,
consistent with the observed degree of pathological change.
Interestingly, the pattern of metabolite changes identiﬁed in this
study does not correlate well with the gradient of degeneration com-
monly observed in post-mortem HD brains [30]. Surprisingly, whilst
the putamen is pathologically the most affected area, the hippocampusand the cerebellumwere among those regionswherein high numbers of
metabolite alterations were observed. Volume loss is not commonly as-
sociatedwith the hippocampus and the cerebellum, however cerebellar
and hippocampal pathology has been reported in both juvenile-onset
and adult-onset HD [31–34]. Another unexpected result was the small
number of changes in metabolite abundance in HD motor cortex.
Here we found several important processes to be altered in HD
brains, including glucose and the polyol-pathway intermediates, sorbi-
tol and fructose along with metabolites implicated in brain energetics,
TCA cycle, urea cycle and amino acid metabolism. Brain energy supply
is known to be dysfunctional in HD [35–38]. For example, PET studies
indicate that glucose consumption is reduced in the basal ganglia of
HD gene-carriers, even at the premanifest stage [39,40]. In our study,
we observed a marked accumulation of glucose in the basal ganglia as
well as those brain regions closely related to this circuit: these results in-
dicate impaired glucose utilization in these regions in HD. Notably, of
the eleven brain regions analysed here, putamen was the sole region
where the concomitant upregulation of glucose, sorbitol and fructose
was observed. To our knowledge, this is the ﬁrst report showing in-
creased levels in HD of all three sugars comprising the members of the
polyol pathway. In the brain, sorbitol and fructose are commonly
formed from glucose via the polyol pathway in astrocytes and neurons
[41] and alterations of this pathway are generally associated with
hyperglycaemia resulting from diabetic complications and have more
recently also been demonstrated in the brain associated with
Alzheimer's disease (AD) [42]. As over-activity in the polyol pathway
may generate cell damage via osmotic stress or chemical toxicity of glu-
cose and fructose, our results indicate that this mechanismmaywell act
as a potential player in the profound neurodegeneration observed in the
putamen in HD [43]. While it is unclear to date how mHtt might cause
excessive activation of the polyol pathway in the HD putamen, it
would be valuable to determine whether equivalent over-activation of
the polyol pathway is also evident in the in vitro and in vivo animal
models where a human HD mutation is expressed.
Further evidence of dysfunctional energy utilisation in the HD brain
is also provided here by alterations in the levels of alternative fuel sub-
strates such as threitol, glycerol, ribitol, glycerol-3-phosphate, glycerol-
2-phosphate, and their derivates. These metabolites are commonly as-
sociated with essential metabolic pathways used as secondary energy
sources in human tissues. Further indications are provided by the
alterations observed in those metabolites known to participate in
Fig. 3. Correlation heatmaps ofmetabolite co-regulation in control andHD cases in individual brain regions. Heatmaps illustrating the alteration inmetabolite abundance co-regulations in
controls (top panel in each brain region) and HD cases (bottom panel in each brain region). Differences betweenmetabolite abundance co-regulations in controls andHD gene-carriers were
investigated by pair-wise correlation analyses and reported in the above heatmaps as one of the colours of the Pearson correlation coefﬁcient (r) gradient scale (on the right). As illustrated
at the bottom of each heatmap in the panel, the metabolites considered for correlation analyses were separated by classes: sugars (red), fuels (cyan), TCA and urea cycle intermediates
(magenta), amino acids (green), nucleosides (purple) and others (black).
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Fig. 4. Amino acid alterations in individual regions of the HD brain. A simpliﬁed diagram illustrating the relationships between amino acids detected in this study. (A–H). Each panel
summarises the signiﬁcant amino acid changes observed after correction for multiple comparisons in individual HD-brain regions as compared to controls. The abundance of
tryptophan, phenylalanine and tyrosine is solely increased in putamen (A) and in none of the other brain regions examined by GC–MS (B–H). Legend: amino acids increased in
abundance in HD (red diamond); amino acids decreased in abundance in HD (blue diamond); amino acids not altered in abundance in HD (white diamond); metabolites not detected
by our GC–MS method (grey diamond). Abbreviations: NAA (N-acetylaspartic acid).
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GC–MS assay are increased in HD, particularly in the brain regionsmost
severely affected in thedisease. Taken together these observationspoint
to a ‘hypometabolic’ state in theHDbrain coupled to a reactive catabolic
response. For instance, as a result of impaired glucose uptake in the
brain, human organs can use alternative energy sources including ke-
tone bodies, amino acids, or fatty acids in order to maintain nutrient
ﬂow into the TCA cycle. β-hydroxybutyric acid (βHB), a main ketone
body, is generally produced in the liver during ketosis [44], and is
utilised in the brain as an alternative fuel source for acetyl-CoA
oxidation in the TCA cycle when glucose supply is deﬁcient or perhaps
metabolism is dysregulated as occurs in HD, AD and Parkinson's disease
(PD) [39,42,45,46]. As βHB concentration is increased only in a limited
number of the HD brain regions, our data indicates that this ketone
may not be primarily used as a glucose-replacing substrate for energy
production in the HD brain: these ﬁndings would also seem to exclude
the possibility that theHDcases studied herewere subjected to an over-
all ketotic state driven by putative alterations of the hepatic metabolism
[47–49].
Amino-acid degradation is another biochemical mechanism that can
provide substrates for the TCA cycle in order to sustain energy demands
[50]. Here we foundmajor decreases in several classes of amino acids in
the brain of HD mutation-carriers. Among these were: the ketogenic
amino acids lysine and leucine; the glucogenic amino acid methionine;
and the ketogenic/glucogenic amino acids isoleucine and threonine. No-
tably, these amino acids can serve as primary fuel sources formitochon-
drial oxidation via acetyl-CoA and succinyl-CoA, two of the key
intermediates of the TCA cycle. While is not possible to establish the or-
igin of these tissuemetabolites in our study,we hypothesise that the de-
crease in amino acids observed here could reﬂect the need in HD brain
for substrates to funnel into the TCA cycle: Similar mechanisms have
been advanced to account for the diminished levels of branched-chain
amino acids (BCAAs) found in plasma of HD gene-carriers [51].
Finally, theβ-oxidation of fatty acids is also considered to provide an
alternative source to glucose for energy production in the CNS via the
TCA cycle. A number of reports indicate that a part of total energy re-
quirement of the brain is usually fulﬁlled by oxidation of fatty acids
[52–54]. As only the polar components of brain extracts were analysed
for the current study, it is uncertain how fatty acids contained in our
HD samples were affected. Nevertheless, the involvement of fatty-acid
β-oxidation-related metabolites is believed to contribute to the HD-
phenotype signature [14].
In light of theseﬁndings,we hypothesise that the accumulation of TCA
cycle-intermediates observed here in some HD-brain regions may be
indicative of increased oxidation of locally-generated or peripherally-
derived fatty acids. Alternatively, the accumulation of TCA cycle- interme-
diatesmay result from an acquired impairment in the functionality of the
enzymes that catalyse the component reactions that comprise the cycle,
thus converting thesemetabolites into their ﬁnal products and extracting
chemical energy. Consistent with this observation, a number of studies
have shown that several of the enzymeswhich participate in the chemical
reactions of the TCA cycle are functionally impaired in HD [55].
The severe, global accumulation of urea in all brain regions of HD
gene-carriers previously reported from this cohort have potential
implications and themain outcomes are discussed elsewhere [56]. Nev-
ertheless, further ﬁndings reported here shed light on the potential in-
volvement of the urea cycle in HD pathogenesis. For instance,
ornithine, a key intermediate of the urea cycle produced by cleavage
of arginine by arginase to form urea, is predominantly decreased in
theHDbrains analysed here. Altogether, the decrease in ornithine levels
is concomitant with the massive accumulation of urea in HD cases,
pointing to a deﬁciency in the brain-urea clearance system rather than
an impaired functionality of the urea cycle itself; this is consistent
with observations reported by others [57]. On the other hand, this
decrease in ornithine with accompanying urea accumulation could re-
sult from enhanced activity of two of the key enzymes of polyaminesynthesis, namely arginase 1 (ARG1) and ornithine decarboxylase
(ODC). Previous studies have shown that pathologically-elongated
polyQ-proteins can boost the activity of ARG1 and ODC, leading to
enhancement of polyamine production and ultimately to cell death
[58]. This mechanism could be reﬂected at the functional level in our
current data, with increased rates of conversion of arginine by ARG1
to ornithine and subsequently urea. An accumulation of ornithine is
not observed here since our study provides a snapshot of metabolite
concentration, not metabolic ﬂux through a pathway, and ornithine
can be rapidly converted by ODC to a primary substrate for polyamine
synthesis. Further studies measuring the ﬂux through this pathway in
HD should be performed to test this hypothesis.
One of the most interesting ﬁndings reported here is the distinctive
amino-acid signature observed in HD putamen. Indeed, this is the sole
brain regionwhere a group of amino acids sharing a common precursor
were substantially increased in HD cases. The list of these includes the
aromatic amino acids tryptophan, phenylalanine and tyrosine (Fig. 4;
Suppl. Fig. 5).
Tryptophan is an essential amino acid that is closely linked to neuro-
nal survival and immune- system regulation, among other processes
[59,60]; furthermore, it serves as a key substrate for kynurenine-
pathway metabolism [61], and its consumption is thought to be locally
regulated in the brain, as most of the kynurenine-pathway intermedi-
ates do not readily cross the blood-brain barrier [62]. Therefore, we
hypothesise that the conversion of tryptophan to kynurenine, mediated
by the immune-inducible enzyme indoleamine 2,3-dioxygenase (IDO),
might be dysfunctional in the HD putamen, resulting in tryptophan-
accumulation in this region.Whilewe cannot rule out tryptophan levels
being reﬂective of a systemic imbalance in HD [63–65], in the present
study, in contrast to others [66], our results are indicative of a brain
region-speciﬁc accumulation of this metabolite in HD gene-carriers.
Further studies will be necessary to clarify this apparent discrepancy.
The other two aromatic amino acids increased in the HD putamen,
namely phenylalanine and tyrosine, represent the most important
sources of catecholamines in the body and have been previously associ-
atedwith peripheral pathogenesis inHD [49,67]. As phenylalanine is the
main substrate for production of tyrosine via a non-reversible reaction
catalysed by phenylalanine hydroxylase, the localised increase in tyro-
sine levels might be reﬂective of an elevated presence of phenylalanine
in HD putamen. Phenylalanine is an essential amino acid assimilated by
the body through diet and its excessive accumulation is causative of
phenylketonuria (PKU), a genetic disease known to induce brain dam-
age and mental illness in patients [68]. Notably, it has been suggested
that PKU might recapitulate some aspects of amyloid disorders such as
AD and PD [69]. Taken together, our data support a deeper investigation
into the putative role of phenylalanine in HDpathogenesis, especially as
phenylalanine intake can be easily controlled by diet [70].
It should be also noted that purinemetabolism is signiﬁcantly affect-
ed in HD cases in the current study.While hypoxanthine is decreased in
most of the brain regions examined, guanosine, xanthine and inosine
presented heterogeneity of distribution throughout the HD brain.
These three purines are included in the short list of metabolites with
higher %CV values upon analysis of replicate samples: as such their reg-
ulation in the HD brain should be interpreted with care. Nevertheless,
the observation of altered purine metabolism in CNS could be related
to theperipheral dysregulation of purinemetabolites reported by others
in HD [71].
Phosphatidylcholines (PCs) are themost abundant phospholipids in
the CNS and play a primary role in the biosynthesis of new neuronal
membranes and formation of synapses [72]. Ethanolamine serves as im-
portant substrate for the production of PCs via the Kennedy pathway
[73] and is uniformly decreased in many of the HD-brain regions exam-
ined here, namely CG, SN, MTG, CB and HP where neuronal loss is not
prominent. On the other hand, another study has shown that ethanol-
amine decrease is greater in more severely affected HD-brain regions
[74]. Apart from the putamen, where similar ﬁndings were observed,
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frontal lobe was used for analysis, these authors did not measure etha-
nolamine levels in the other brain regions reported here. Taken togeth-
er, our results are consistent with synaptic/membrane dysfunction in
HD [75–77] and suggest that these impairments might be not localized
but widespread throughout the HD brain.
A number of studies have shown how neurotransmitter levels are
commonly altered in neurodegenerative diseases [42,78,79]. To investi-
gate this phenomenon, the levels of GABA, the primary inhibitory neu-
rotransmitter in the CNS, were measured. As anticipated by other
reports, GABA levels are generally decreased in HD cases when com-
pared to controls [80] whereas the abundance of GHB was reportedly
lower in HD cases in multiple brain regions, thus conﬂicting with previ-
ous studies [81]. Themajor difference in post-mortem delay between the
cases used here (6.5–15 h) and in the other studies (22–72 h) might be
in part responsible for the discrepancy observed.
Scyllo-inositol, an isomer of inositol, was reduced in most HD-brain
regions examined here. These results are consistent with dysfunctional
functionality in the inositol-phosphate pathway in HD brain. Notably,
scyllo-inositol has been found to lower the accumulation of amyloid-β
peptide in vivo [82] andα-synuclein andmHtt aggregates/mHtt protein
in vitro [83,84]. In HD cells, the clearance mechanism is reportedly me-
diated by proteasomes and lysosomes, which promote mHtt aggrega-
tion and protein degradation [84]. Our results might therefore suggest
that scyllo-inositol is involved, along with other factors, in the modula-
tion of clearance-activationmechanisms in a compensatory response to
mHtt aggregate-formation and polyQ-Htt accumulation in HD brain.
The presence of altered inositol phosphate metabolism in HD is also
supported by changes in myo-inositol levels. In the CNS, myo-inositol
represents 90% of total inositol and can be readily interconverted to
scyllo-inositol [85]. This metabolite is often considered a marker of
gliosis and is commonly monitored by magnetic resonance spectrosco-
py (MRS) [86,87]. However, the validity of myo-inositol as a gliosis-
marker is yet to be proven [88] and there is still little agreement about
how its levels are perturbed in HD [89,90]. In the present study, our re-
sults point to a broad decrease in myo-inositol in multiple brain regions
in HD cases. The differences in sample size, brain region dissected, HD
severity and themethod appliedmight in part be responsible for the ob-
served dissimilarities between our study and other reports [89,90].
Changes in myo-inositol levels are not solely associated with gliosis in
the CNS, but may also be indicative of tissue-osmolality disequilibrium
[91,92], as this metabolite acts as an organic osmolyte that participates
in cell-volume regulation [93,94]. For instance in hepatic encephalopa-
thy, brain myo-inositol depletion has been shown to counteract the as-
trocyte swelling caused by intracellular accumulation of glutamine in
response to hyperammonaemia [95–99]. Notably, hyperammonaemia
and other urea cycle-related defects have been associated with HD
[100]. Taken together, the observed myo-inositol decrease could be in-
dicative of a compensatory mechanism triggered by HD-damaged cells
to counteract increased brain-ammonia levels. In light of this
observation, it will be of interest to measure ammonia levels in
suitably-prepared post-mortem HD brain. Finally, as the accumulation
of myo-inositol seems to correlate with the degree of HTT CAG-repeat
expansion in the putamen, we suggest that a direct link might exist
between HTT mutation length, the inositol phosphate pathway, tissue
osmolality and the severity of neurodegeneration in HD.
Since there are few comparable metabolite-proﬁling studies on
human brains affected by neurodegenerative disorders available in the
literature, our ability to discriminate between disease-speciﬁc HD
phenotypes from those identiﬁed as a consequence of generalised neu-
rodegeneration have been hampered to date. Furthermore, the capabil-
ity of comparing across different metabolite studies is also complicated
by a number of variables, such asmode of specimen collection and stor-
age, sample preparation, the exact methodology used, and criteria ap-
plied for data analysis. To overcome some of these limitations, our
group, in parallel with the present study, has also performed detailedmetabolite proﬁling of post-mortem AD brains [42]. Since both studies
shared the same source of samples (i.e. human brain bank, University
of Auckland), similar classes of brain regions analysed, and the same
GC–MS methodologies/data processing applied, we believe that the
qualitative comparison of these valuable datasetsmay provide potential
indications of HD-speciﬁc metabolic signatures. In fact, while some al-
terations can be observed in common between AD and HD, for example
global decrease in some neurotransmitter levels, distinctmetabolite sig-
natures emerge in HD brains. For instance, whereas polyol pathway-
related metabolites, namely glucose, sorbitol and fructose, increase
steadily according to the known pathological gradient in AD brain, in
HD the accumulation of these metabolites is limited to the putamen
and is not heavily inﬂuenced by thewidespread degeneration occurring
in other HD brain regions. The aromatic amino acids tryptophan and ty-
rosine, which share chorismic acid as their common precursor, seem to
be distinctively modulated in HD. In fact, while the tryptophan/tyrosine
ratio is approximately in equilibrium in HD brain, whether the region
considered undergoes severe degeneration or not, in AD brain this
ratio is predominantly weighted towards tryptophan and correlated
with disease severity. Finally, scyllo-inositol alterations were solely as-
sociated with HD brain in these studies. Taken together, the results
of these comparative observations, although purely qualitative at this
stage, may indicate variation in metabolite abundances which are per-
haps solely associated with HD and which deserves further
investigation.
This study has limitations. Suppl. Table 1 provides information in-
cluding cause of death in controls and cases: this was the primary
cause listed on the death certiﬁcate. The table includes a column show-
ing the neuropathological grade of each HD case (i.e. Vonsattel Grade),
which indicates the degree of caudate-putamen degeneration at the
time of death [18]. Six cases whose Vonsattel Grades varied from 1
(mildly affected) to 4 (most severely affected), had bronchopneumonia
listed as the cause of death: thus bronchopneumonia was the most fre-
quent cause of death in this group of HD patients andwas not related to
Vonsattel pathological grade. The age at death varied considerably
(between 51 and 83 yrs), as frequently occurs in such patients, although
expanded CAG repeat numbers varied between 40 and 47. Due to the
insidious nature of the disease, age at onsetwas not indicated. Vonsattel
Grades differed somewhat between brains, which could possibly have
weakened correlations for some molecules, so correlations may have
been even higher had all brains been at the same stage. The Vonsattel
Grades of these HD patients are consistent with varying degrees of
degeneration of the caudate-putamen, which displayed early to late
pathological grades: however, all of these HD patients demonstrated
uniform alterations in different classes of polar metabolites in the
striatal portion of the brain (i.e. glucose, sorbitol and fructose). We
aimed to identify and map regional alterations in metabolite levels
across a large portion of the HDbrain, using a strategy based onmaterial
with short-post-mortem delay. Limitations of such post-mortem analyses
must therefore be considered. First, we should reﬂect on the possible
effect that PMD could exert on brain metabolites. In fact, although our
samples were matched for PMD, and signiﬁcant associations of PMD
with accumulation or reduction of metabolites were not detected by
correlational analyses, we cannot completely exclude the possibility
that degradation of some metabolites might have occurred in our
human-brain samples soon after death: consequently, we cannot
establish with certainty how such an artefact might have inﬂuenced
our analyses. However, the case-control design we employed can be
expected to mitigate against this limitation, at least to some extent.
Another limitation consists in the relatively small number of cases
generally used in post-mortem studies. While the number of specimens
analysed here (ca. 300) allowed us to establish a robust and reproduc-
ible GC–MS workﬂow for analysis of post-mortem brain samples, a
follow-up study based on larger cohorts is recommended to validate
and extend our initial ﬁndings, and eventually to unmask small-to-
moderate effect sizes in metabolite abundances. In addition, it is
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present study may represent secondary effects caused by an unknown
primary mechanism responsible for metabolic alteration in HD. Thus,
even if these alterationsmight be potentially regarded as compensatory
or harmful responses potentially linked to the metabolic signature of
HD, further studies are necessary to elucidate how the causative HTT
mutation is precisely inﬂuencing HD metabolism. Finally, it would be
of interest to establish at what stage of the disease progression the me-
tabolite alterations described in this study might ﬁrst occur. Even so, it
should be reminded that post-mortem human studies have
enormously contributed so far to our knowledge about critical aspects
of neurodegenerative diseases and drug-design for these disorders
[101,102].
5. Conclusion
We have here identiﬁed and mapped a widespread pattern of
metabolic perturbations in eleven regions of post-mortem brain from
patients who died with HD. Moreover, several of the metabolite
alterations identiﬁed here as contributing to the disease signature
were found to be correlated with expansion of the causative HD muta-
tion. As the huntingtin protein is ubiquitously expressed in brain but
only limited areas are apparently subject to the severe structural
consequences of its toxic effects in HD, the region-speciﬁc metabolic
signatures identiﬁed in this study lay the foundations for a better under-
standing of how themutant HDproteinmight cause localisedmetabolic
perturbations in the CNS, and of whichmolecularmechanismsmight be
activated in speciﬁc regions to counterbalance these perturbations. Ulti-
mately, the need for a better understanding of the mechanisms by
which metabolic aberrations exert their inﬂuence on HD phenotype is
acute. It is hoped that the ﬁndings presented here will serve as a useful
platform to identify mechanisms suitable for pharmacological targeting
to rapidly develop new and effective experimental therapies for HD for
translation into the clinic.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2016.06.002.
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